Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Thorac Oncol
    June 2026
  1. DACIC S, Shenker D, Redman M, Brunner L, et al
    Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR Project.
    J Thorac Oncol. 2026 Jun 1:103953. doi: 10.1016/j.jtho.2026.103953.
    >> Share

    May 2026
  2. KATSUMATA S, Kamigaichi A, Akamine T, Isaka M, et al
    Segmentectomy versus lobectomy in non-small-cell lung cancer with pathologically invasive features: a post-hoc supplementary analysis of a multicenter, Phase 3 trial JCOG0802/WJOG4607L.
    J Thorac Oncol. 2026 May 11:103916. doi: 10.1016/j.jtho.2026.103916.
    >> Share

  3. DEL RIO B, Masini S, Caceres-Galvis C, Torres-Jimenez J, et al
    Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2026 May 2:103899. doi: 10.1016/j.jtho.2026.103899.
    >> Share

  4. D'ANGELILLO RM, Ramella S
    Heart-Sparing Radiotherapy in Patients With Lung Cancer.
    J Thorac Oncol. 2026;21:103612.
    >> Share

  5. ERASMUS JJ, Vlahos I
    Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective.
    J Thorac Oncol. 2026;21:103563.
    >> Share

  6. TAFENZI HA, Essadi I, Belbaraka R
    Lung Cancer in Morocco.
    J Thorac Oncol. 2026;21:103561.
    >> Share

  7. TUMINELLO S, Joyama Y, Taioli E
    Genetic Predisposition to Lung Cancer Is Modulated by Sex, Smoking, and Ancestry.
    J Thorac Oncol. 2026;21:103559.
    >> Share

  8. DREVET G, Kalson L, Mange L, Galateau-Salle F, et al
    Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
    J Thorac Oncol. 2026;21:103551.
    >> Share

  9. GUO H, Wang Y, Diao M, Han R, et al
    Bispecific T-cell Engager (CD3 x EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.
    J Thorac Oncol. 2026;21:103607.
    >> Share

    April 2026
  10. KOGA T, Ogawa H, Radulovich N, Pham NA, et al
    Endobronchial Ultrasound-Guided Biopsy Derived Lung Cancer Models: A Platform for Precision Therapy.
    J Thorac Oncol. 2026 Apr 27:103893. doi: 10.1016/j.jtho.2026.103893.
    >> Share

  11. HUANG J, Chen G, Wang Z, Jin W, et al
    Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial.
    J Thorac Oncol. 2026 Apr 22:103737. doi: 10.1016/j.jtho.2026.103737.
    >> Share

  12. STEWART CA, Ramkumar K, Wang R, Xi Y, et al
    YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.
    J Thorac Oncol. 2026 Apr 20:103730. doi: 10.1016/j.jtho.2026.103730.
    >> Share

  13. MONACA F, Gomez-Randulfe I, Torres-Jimenez J, Agarwal M, et al
    Antibody-Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond.
    J Thorac Oncol. 2026 Apr 13:103726. doi: 10.1016/j.jtho.2026.103726.
    >> Share

  14. ARDESHIR-LARINANI F, Ashrafian L, Chiappetta M, Mansilla D, et al
    Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.
    J Thorac Oncol. 2026 Apr 10:103611. doi: 10.1016/j.jtho.2026.103611.
    >> Share

  15. LU S, Fang J, Yu Y, Fan Y, et al
    SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
    J Thorac Oncol. 2026 Apr 6:103713. doi: 10.1016/j.jtho.2026.103713.
    >> Share

  16. MCMAHON RA, Lee Min Chua K, Faivre-Finn C, Filippi AR, et al
    Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.
    J Thorac Oncol. 2026 Apr 3:103643. doi: 10.1016/j.jtho.2026.103643.
    >> Share

  17. LU J, Shum E, Samstein RM, Prada D, et al
    Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.
    J Thorac Oncol. 2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.
    >> Share

  18. STOCKHAMMER P, El Zarif T, Schillo JL, Li F, et al
    ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
    J Thorac Oncol. 2026 Apr 1:103708. doi: 10.1016/j.jtho.2026.103708.
    >> Share

  19. PUJOL JL, Milleron B, Bommart S
    Screening Lung Cancer in Population-Based Real-World Programs: Searching for Efficiency Indicators.
    J Thorac Oncol. 2026;21:103539.
    >> Share

  20. SALAMA JK, Mix MD, Faivre-Finn C, Bezjak A, et al
    The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress.
    J Thorac Oncol. 2026;21:103578.
    >> Share

  21. ORTIZ-CUARAN S, Dupriez L, Nicq C, Lindsay CR, et al
    Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
    J Thorac Oncol. 2026;21:103531.
    >> Share

  22. BURNS TF, Ammakkanavar NR, Hollebecque A, Lee DH, et al
    Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.
    J Thorac Oncol. 2026;21:103528.
    >> Share

  23. SEVERSON DT, Freyaldenhoven S, Wadowski B, Hung YP, et al
    Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype.
    J Thorac Oncol. 2026;21:103529.
    >> Share

  24. PHAM R, Garama D, Malhotra A, Kwok A, et al
    Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy.
    J Thorac Oncol. 2026;21:103522.
    >> Share

    March 2026
  25. PARISI C, De Giglio A, Banini M, Tagliamento M, et al
    Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care.
    J Thorac Oncol. 2026 Mar 30:103705. doi: 10.1016/j.jtho.2026.103705.
    >> Share

  26. FUKUDA A, Fukami T, Nomura K, Kashima J, et al
    Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
    J Thorac Oncol. 2026 Mar 26:103693. doi: 10.1016/j.jtho.2026.103693.
    >> Share

  27. RUSSO A, Javey M, Huang RSP, Yaung SJ, et al
    Molecular Profiling across 80,000 Patients with Lung Cancer.
    J Thorac Oncol. 2026 Mar 26:103695. doi: 10.1016/j.jtho.2026.103695.
    >> Share

  28. YANG SR, Tjota MY, Goren E, Giroux DJ, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9(th) Edition Staging Database.
    J Thorac Oncol. 2026 Mar 13:103681. doi: 10.1016/j.jtho.2026.103681.
    >> Share

  29. PONCE S, Ruiz-Torres M, Falcon A, Cote GM, et al
    Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2026 Mar 4:103654. doi: 10.1016/j.jtho.2026.103654.
    >> Share

  30. TRIPHURIDET N, Ou SI
    The "Inflammatory-Mutagenic" Landscape of Systemic Sclerosis (SSc)-Associated Lung Cancer: Distinct Genomics and Therapeutic Implications.
    J Thorac Oncol. 2026;21:103536.
    >> Share

  31. AGRAFIOTIS AC, Rami-Porta R, Altorki N, Van Schil PE, et al
    Journal of Thoracic Oncology 20th Anniversary Series Surgery.
    J Thorac Oncol. 2026;21:103530.
    >> Share

  32. RECK M, Patel JD, Gray JE, Reguart N, et al
    First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
    J Thorac Oncol. 2026;21:103509.
    >> Share

  33. PENG LS, Cui Q, Zhang C, Lin JT, et al
    Neoadjuvant Immunochemotherapy in Resectable NSCLC With SMARCA4 Alterations.
    J Thorac Oncol. 2026;21:103506.
    >> Share

  34. CHEN MF, Lee JJ, Choudhury NJ, Hui AB, et al
    Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
    J Thorac Oncol. 2026;21:103505.
    >> Share

  35. ODINTSOV I, Hammer MM, Ricciuti B, Pecci F, et al
    The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes.
    J Thorac Oncol. 2026;21:103501.
    >> Share

  36. ZHANG X, Wen Y, Wu F, Jiang Y, et al
    GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2026;21:103494.
    >> Share

    February 2026
  37. ILLINI O, Hund AC, Kopp HG, Moskovitz M, et al
    Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.
    J Thorac Oncol. 2026 Feb 24:103651. doi: 10.1016/j.jtho.2026.103651.
    >> Share

  38. GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
    Corrigendum to 'Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial' [Journal of T
    J Thorac Oncol. 2026 Feb 24:103558. doi: 10.1016/j.jtho.2026.103558.
    >> Share

  39. ZANGHI A, Moro M, Fortunato O, Segale M, et al
    Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening.
    J Thorac Oncol. 2026 Feb 16:103614. doi: 10.1016/j.jtho.2026.103614.
    >> Share

  40. ZALCMAN G, Madroszyk A, Guenzi E, Dayen C, et al
    Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial.
    J Thorac Oncol. 2026 Feb 12:103609. doi: 10.1016/j.jtho.2026.103609.
    >> Share

  41. VAN MEERBEECK JP, Bousema JE, Wen W, Van Schil PEY, et al
    Staging of Lung Cancer: A Call for Developing Uniform and Universal Key Performance Indicators and Benchmarks to Elevate Clinical Standards.
    J Thorac Oncol. 2026;21:253-257.
    >> Share

  42. LAM S, Baldwin DR, Devaraj A, Field J, et al
    A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.
    J Thorac Oncol. 2026;21:235-252.
    >> Share

  43. AL-KHAFAJI ASK, Al-Alloosh F, Alabedi HH, Al-Obaidi KMA, et al
    Lung Cancer in Iraq.
    J Thorac Oncol. 2026;21:227-234.
    >> Share

  44. DI FRISCO M, Sanmamed MF, Ferrandez JM, Vilalta A, et al
    Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2026;21:328-333.
    >> Share

  45. LE X, Baik C, Cho BC, Riess JW, et al
    Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    J Thorac Oncol. 2026;21:318-327.
    >> Share

  46. MINO-KENUDSON M, Berezowska S, Minami Y, Chen S, et al
    A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee.
    J Thorac Oncol. 2026;21:294-309.
    >> Share

  47. PECCI F, Agrawal P, Ross JS, Ricciuti B, et al
    Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
    J Thorac Oncol. 2026;21:310-317.
    >> Share

    January 2026
  48. NOVELLO S, Cheng Y, Spigel D, Fang J, et al
    Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial.
    J Thorac Oncol. 2026 Jan 30:103564. doi: 10.1016/j.jtho.2026.103564.
    >> Share

  49. MANKUZHY NP, Santo V, Shin JY, Chaunzwa TL, et al
    Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy.
    J Thorac Oncol. 2026 Jan 29:103565. doi: 10.1016/j.jtho.2026.103565.
    >> Share

  50. LEE CK, Lefresne S, Soon YY, Robledo K, et al
    Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials.
    J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00001.
    >> Share

  51. HAN IS, Ko K, Zou JW, Smith AM, et al
    Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer.
    J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00002.
    >> Share

  52. CARBONE M, Amos C, Attanoos RL, Boeri M, et al
    Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.
    J Thorac Oncol. 2026;21:41-76.
    >> Share

  53. WU H, Fu F, Ye T, Hu H, et al
    Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021).
    J Thorac Oncol. 2026;21:150-159.
    >> Share

  54. KIM YW, Jung S, Kim SJ, Kang HR, et al
    Trajectories of Synchronous Subsolid Nodules in Patients With Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study.
    J Thorac Oncol. 2026;21:174-185.
    >> Share

  55. TAKAHASHI S, Taki T, Nakamura N, Ura A, et al
    Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples.
    J Thorac Oncol. 2026;21:135-149.
    >> Share

  56. BRUNE MM, Roma L, Chijioke O, Alborelli I, et al
    MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC.
    J Thorac Oncol. 2026;21:112-123.
    >> Share

  57. HULBERT A, Tiv R, Cao B, Cesario D, et al
    CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.
    J Thorac Oncol. 2026;21:124-134.
    >> Share

  58. JUANG YR, Zhao Q, Pyng L, Seow WJ, et al
    REMOVED: PP01.04: Lung Cancer Risk Factors in Singapore: A Systematic Review and Meta-analysis With Comparative Insights From Across Asia.
    J Thorac Oncol. 2026;21.
    >> Share

    December 2025
  59. TANIMOTO A, Ramkumar K, Stewart CA, Zhang B, et al
    The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer.
    J Thorac Oncol. 2025 Dec 26:S1556-0864(25)03066.
    >> Share

  60. PLANCHARD D, Kim HR, Suksombooncharoen T, Li R, et al
    Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
    J Thorac Oncol. 2025 Dec 23:S1556-0864(25)03021.
    >> Share

  61. LIU Y, Li Y, Byun J, Shaw VR, et al
    High penetrance rare variants underlying familial lung cancer risk: Insights from genetic epidemiology of lung cancer consortium.
    J Thorac Oncol. 2025 Dec 11:S1556-0864(25)02942.
    >> Share

  62. GOODLEY P, Balata H, Alonso A, Sharman A, et al
    Population impact of risk-based lung cancer screening on late-stage incidence in Greater Manchester.
    J Thorac Oncol. 2025 Dec 2:S1556-0864(25)02908.
    >> Share

  63. FADUL MJS, Mendoza MJL, Sacdalan DBL, Samala KG, et al
    Lung Cancer in the Philippines.
    J Thorac Oncol. 2025;20:1747-1752.
    >> Share

  64. BOLAND JM, Lo YC, Mansfield AS
    Immune Checkpoint Inhibitor Monotherapy for Patients With Pulmonary Sarcomatoid Carcinoma-The Optimal Therapeutic Strategy for This Rare Lung Cancer Subtype?
    J Thorac Oncol. 2025;20:1735-1736.
    >> Share

  65. YEH YC, Chiang CH, Hsu PK, Wang LC, et al
    Tumor Cell Invasion of the External Elastic Lamina Designates Visceral Pleural Invasion and Predicts Poorer Patient Outcomes in Pulmonary Nonmucinous Invasive Adenocarcinoma.
    J Thorac Oncol. 2025;20:1791-1800.
    >> Share

  66. HONG L, Di Federico A, Liu B, Cooper AJ, et al
    Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
    J Thorac Oncol. 2025;20:1763-1777.
    >> Share

  67. PETERS S, Schulz C, Reck M, Prabhash K, et al
    Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
    J Thorac Oncol. 2025;20:1843-1850.
    >> Share

    November 2025
  68. ROSS JS, Thummalapalli R, Febres-Aldana CA, Muldoon D, et al
    Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Nov 17:S1556-0864(25)02904.
    >> Share

  69. YANG JJ, Mu Y, Wang ZH, Duan JC, et al
    Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study.
    J Thorac Oncol. 2025 Nov 15:S1556-0864(25)02902.
    >> Share

  70. ZHU H, Al Saifi S, Bahig H, Cooper A, et al
    Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subc
    J Thorac Oncol. 2025 Nov 14:S1556-0864(25)02899.
    >> Share

  71. MIYAKOSHI J, Shiraishi K, Mochizuki A, Tateishi A, et al
    Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Nov 7:S1556-0864(25)02894.
    >> Share

  72. CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
    Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic O
    J Thorac Oncol. 2025 Nov 1:S1556-0864(25)02853.
    >> Share

  73. ADJEI AA
    Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal.
    J Thorac Oncol. 2025;20:1559-1560.
    >> Share

  74. ZHOU T, Terry OC, Minton KG, Poole L, et al
    Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma.
    J Thorac Oncol. 2025;20:1716-1721.
    >> Share

  75. LEE SH, Lu S, Hayashi H, Felip E, et al
    Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
    J Thorac Oncol. 2025;20:1655-1668.
    >> Share

  76. CARBONE M, Minaai M, Kittaneh M, Krausz T, et al
    Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations.
    J Thorac Oncol. 2025;20:1683-1698.
    >> Share

  77. DAGOGO-JACK I, Mitchell O, Codd E, Li A, et al
    Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations.
    J Thorac Oncol. 2025;20:1615-1625.
    >> Share

  78. MITSUDOMI T, Heymach JV, Reck M, Taube JM, et al
    Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
    J Thorac Oncol. 2025;20:1639-1654.
    >> Share

  79. AHN MJ, Lisberg A, Goto Y, Sands J, et al
    A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
    J Thorac Oncol. 2025;20:1669-1682.
    >> Share

  80. CHO H, Shiraishi K, Sunami K, Momozawa Y, et al
    Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:1626-1638.
    >> Share

    October 2025
  81. LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
    Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
    J Thorac Oncol. 2025 Oct 27:S1556-0864(25)02849.
    >> Share

  82. ALLGAUER M, Kluck K, Christopoulos P, Ball M, et al
    Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins.
    J Thorac Oncol. 2025 Oct 22:S1556-0864(25)02857.
    >> Share

  83. KIM SY, Silvestri GA, Park YS
    A Response to Letter to the Editor: "Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study".
    J Thorac Oncol. 2025;20:e115-e116.
    >> Share

  84. ZHAO D, Li W, Li W
    Screening for Lung Cancer, Overdiagnosis, and Health Care Utilization: A Nationwide Population-Based Study.
    J Thorac Oncol. 2025;20:e114-e115.
    >> Share

  85. GENDARME S, Chouaid C, Ostrin E
    Comorbidities in Lung Cancer Screening: A Key to Finding the Right Spot or Opening Pandora's Box?
    J Thorac Oncol. 2025;20:e112-e113.
    >> Share

  86. WU Y, Liang Y, Liang J
    Exploring the Impact of Comorbidities on Lung Cancer Screening Mortality Benefits: Insights and Suggestions for Methodological Enhancement.
    J Thorac Oncol. 2025;20:e111-e112.
    >> Share

  87. XIE D, Xu W
    Response to the Letter to the Editor: "Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity".
    J Thorac Oncol. 2025;20:e104-e105.
    >> Share

  88. GAO BY, Lee YT
    Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity.
    J Thorac Oncol. 2025;20:e103-e104.
    >> Share

  89. CHO BC, Li W, Spira AI, Sauder M, et al
    Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
    J Thorac Oncol. 2025;20:1517-1530.
    >> Share

  90. RIELY GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, et al
    Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
    J Thorac Oncol. 2025;20:1538-1547.
    >> Share

  91. LEIGHL NB, Paz-Ares L, Abreu DR, Hui R, et al
    LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.
    J Thorac Oncol. 2025;20:1489-1504.
    >> Share

  92. ZHOU F, Zhang J, Ren S, Chen J, et al
    Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.
    J Thorac Oncol. 2025;20:1475-1488.
    >> Share

  93. YAO Z, Tang M, Jin Y, Ruan J, et al
    Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development
    J Thorac Oncol. 2025;20:1531-1537.
    >> Share

    September 2025
  94. KIM H, Jo E, Kim J, Jang SH, et al
    Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality.
    J Thorac Oncol. 2025 Sep 4:S1556-0864(25)01038.
    >> Share

  95. CHEN CC, Chen SC
    Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
    J Thorac Oncol. 2025;20:e99-e100.
    >> Share

  96. RODE MM, Midthun DE
    A Response to the Letter to the Editor: Cost-Efficiency of Risk-Based Lung Cancer Screening Across PLCOm2012 Risk Deciles.
    J Thorac Oncol. 2025;20:e100-e101.
    >> Share

  97. LEONG TL, Steinfort DP
    Broadening the Scope of Bronchoscopic Sampling in the Era of Minimally Invasive and Molecular Diagnosis of Lung Cancer.
    J Thorac Oncol. 2025;20:1172-1176.
    >> Share

  98. DE GROOT P, Erasmus J, Vlahos I
    Lung Cancer Screening: Future Opportunities.
    J Thorac Oncol. 2025;20:1152-1155.
    >> Share

  99. PARK S, Ahn HK, Lee S, Min YJ, et al
    Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
    J Thorac Oncol. 2025;20:1279-1288.
    >> Share

    August 2025
  100. KENMOTSU H, Saito Y, Ninomiya K, Uematsu S, et al
    Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME).
    J Thorac Oncol. 2025 Aug 18:S1556-0864(25)01014.
    >> Share

  101. ENG L, Evans WK, Eisele M, Nishimura KK, et al
    The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
    J Thorac Oncol. 2025 Aug 4:S1556-0864(25)00824.
    >> Share

  102. HERBST RS, Prizant H, Ruderman D, Conway J, et al
    Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials.
    J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00983.
    >> Share

  103. BANERJEE A, Vathiotis I, Halder D, Sen U, et al
    Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity.
    J Thorac Oncol. 2025 Aug 2:S1556-0864(25)00773.
    >> Share

  104. AL-RABI K, El Khatib O, Abdeljalil R, Talab Y, et al
    Lung Cancer in Jordan.
    J Thorac Oncol. 2025;20:1007-1017.
    >> Share

  105. NAKAZAWA S, Pecci F, Ricciuti B, Gottlieb FH, et al
    Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
    J Thorac Oncol. 2025;20:1035-1049.
    >> Share

  106. ZHANG B, Shah KB, Parma M, Wang K, et al
    Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report.
    J Thorac Oncol. 2025;20:1131-1138.
    >> Share

    July 2025
  107. JANNE PA, Goto Y, Kubo T, Ninomiya K, et al
    Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer.
    J Thorac Oncol. 2025 Jul 30:S1556-0864(25)00981.
    >> Share

  108. CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
    The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
    J Thorac Oncol. 2025 Jul 28:S1556-0864(25)00813.
    >> Share

  109. SMELTZER MP, King JC, Connolly C, Brunson K, et al
    The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing.
    J Thorac Oncol. 2025 Jul 22:S1556-0864(25)00937.
    >> Share

  110. ALDEA M, Rotow JK, Arcila M, Hatton M, et al
    Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2025 Jul 7:S1556-0864(25)00831.
    >> Share

  111. NAIDOO J, Niroula A, Uprety D, Smeltzer M, et al
    50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.
    J Thorac Oncol. 2025 Jul 3:S1556-0864(25)00819.
    >> Share

  112. JIN D, Wu J, Xing W
    Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations.
    J Thorac Oncol. 2025;20:e89-e90.
    >> Share

  113. TAYLOR KL, Williams RM, Meza R, Smith P, et al
    Reducing Lung Cancer Mortality by Providing Smoking Cessation Support in the Lung Cancer Screening Setting: Missed Opportunities and Lessons Learned on Both Sides of the Atlantic.
    J Thorac Oncol. 2025;20:847-855.
    >> Share

  114. BRUSTUGUN OT, Gronberg BH, Aanerud M, Paulsen EE, et al
    Lung Cancer in Norway.
    J Thorac Oncol. 2025;20:839-846.
    >> Share

  115. KILICKAP S, Baramidze A, Sezer A, Ozguroglu M, et al
    Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
    J Thorac Oncol. 2025;20:941-954.
    >> Share

  116. WU YL, Kim HR, Soo RA, Zhou Q, et al
    First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.
    J Thorac Oncol. 2025;20:955-968.
    >> Share

    June 2025
  117. FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al
    Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.
    J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766.
    >> Share

  118. PETERS S, Regan MM, Paz-Ares LG, Reck M, et al
    Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
    >> Share

  119. MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al
    Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
    >> Share

  120. TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al
    A Response to the Letter to the Editor: "Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?".
    J Thorac Oncol. 2025;20:e69-e71.
    >> Share

  121. MEERBEECK JV, Hal GV, Snoeckx A
    Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?
    J Thorac Oncol. 2025;20:e68-e69.
    >> Share

  122. REVEL MP
    Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy.
    J Thorac Oncol. 2025;20:705-707.
    >> Share

  123. FU F, Chen H
    Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
    J Thorac Oncol. 2025;20:703-704.
    >> Share

  124. SCHEFFLER M, Wolf J, Michels S
    Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
    J Thorac Oncol. 2025;20:692-694.
    >> Share

  125. SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al
    Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
    J Thorac Oncol. 2025;20:809-816.
    >> Share

  126. MAO S, Liu X, Wang L, Wang Y, et al
    AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.
    J Thorac Oncol. 2025;20:739-749.
    >> Share

    May 2025
  127. CHADDHA U, Agrawal A, Ghori U, Kheir F, et al
    Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practic
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00722.
    >> Share

  128. HERBST RS, Cho BC, Zhou C, Burotto M, et al
    Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00724.
    >> Share

  129. KREBS MG, Cho BC, Hiret S, Han JY, et al
    Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
    J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
    >> Share

  130. RODE MM, Sykes AG, Allen MS, Ingalls LA, et al
    Risk-Based Lung Cancer Screening in Clinical Practice.
    J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
    >> Share

  131. JONES SB, Chan C, Filippi AR, Harada K, et al
    Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
    J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
    >> Share

  132. WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
    Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
    J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
    >> Share

  133. SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al
    Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
    J Thorac Oncol. 2025 May 2:S1556-0864(25)00699.
    >> Share

  134. BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
    Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
    J Thorac Oncol. 2025;20:e63-e64.
    >> Share

  135. WANG F, Bao M, Zhu L
    Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
    J Thorac Oncol. 2025;20:e62-e63.
    >> Share

  136. MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
    Lung Cancer in Tanzania.
    J Thorac Oncol. 2025;20:560-564.
    >> Share

  137. DE-TORRES JP, Varo N
    The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
    J Thorac Oncol. 2025;20:555-556.
    >> Share

  138. YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
    Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
    J Thorac Oncol. 2025;20:676-679.
    >> Share

  139. LINDBERG A, Muhl L, Yu H, Hellberg L, et al
    In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
    J Thorac Oncol. 2025;20:625-640.
    >> Share

    April 2025
  140. GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al
    High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696.
    >> Share

  141. GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
    Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693.
    >> Share

  142. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
    J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656.
    >> Share

  143. BOERI M, Zanghi A, Pastorino U
    New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
    J Thorac Oncol. 2025;20:422-424.
    >> Share

  144. KIM YW, Lee CT
    Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
    J Thorac Oncol. 2025;20:419-421.
    >> Share

  145. PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
    Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
    J Thorac Oncol. 2025;20:411-414.
    >> Share

  146. XIA Y, Wang K, Zhao J, Arter Z, et al
    Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
    J Thorac Oncol. 2025;20:465-474.
    >> Share

  147. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    J Thorac Oncol. 2025;20:487-499.
    >> Share

  148. BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
    Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
    J Thorac Oncol. 2025;20:521-530.
    >> Share

  149. LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
    Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
    J Thorac Oncol. 2025;20:451-464.
    >> Share

    March 2025
  150. SEDER CW, Chang SC, Towe CW, Puri V, et al
    Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (
    J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641.
    >> Share

  151. HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al
    Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).
    J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106.
    >> Share

  152. CHEN P, Wang H, Tang Z, Shi J, et al
    Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
    J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109.
    >> Share

  153. BROWN M, Myers R, Lam S
    Enlarging the Reach of Screening and Early Detection of Lung Cancer.
    J Thorac Oncol. 2025;20:249-251.
    >> Share

  154. CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
    Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2025;20:311-330.
    >> Share

  155. LU S, Wu L, Wang Q, Wang Z, et al
    Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    J Thorac Oncol. 2025;20:366-382.
    >> Share

  156. MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
    Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Thorac Oncol. 2025;20:285-295.
    >> Share

    February 2025
  157. XIE D, Zhang L, He N, Yang C, et al
    Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China.
    J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072.
    >> Share

  158. CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al
    Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study.
    J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064.
    >> Share

  159. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    Corrigendum to 'The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer' [Journal of Thoraci
    J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050.
    >> Share

  160. HAN B, Liu J, Wu L, Zhao Y, et al
    Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062.
    >> Share

  161. LI YS, Yu Q, Bu Q, Lin L, et al
    First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063.
    >> Share

  162. ABBAR B, Labreche K, Cadranel J, Veyri M, et al
    HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060.
    >> Share

  163. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Failure to Include Nonsmokers in Computed Tomography Screening for Lung Cancer is Unjust".
    J Thorac Oncol. 2025;20:e39-e40.
    >> Share

  164. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges".
    J Thorac Oncol. 2025;20:e36-e37.
    >> Share

  165. LI J, Zhang Y, Fu T, Tong Y, et al
    Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges.
    J Thorac Oncol. 2025;20:e35-e36.
    >> Share

  166. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening".
    J Thorac Oncol. 2025;20:e34.
    >> Share

  167. CUI Y
    Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e33-e34.
    >> Share

  168. RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al
    Lung Cancer in Argentina.
    J Thorac Oncol. 2025;20:144-149.
    >> Share

  169. BAK M, Park H, Lee SH, Lee N, et al
    The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.
    J Thorac Oncol. 2025;20:167-176.
    >> Share

  170. NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al
    Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
    J Thorac Oncol. 2025;20:157-166.
    >> Share

  171. LEE J, Jeon JH, Chung JH, Son JW, et al
    Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma.
    J Thorac Oncol. 2025;20:194-202.
    >> Share

    January 2025
  172. LIAO W, Ray MA, Patel A, Roma J, et al
    Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
    J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057.
    >> Share

  173. BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al
    Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians: An in-depth Analysis of a Nationally Representative Cohort.
    J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053.
    >> Share

  174. TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al
    Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052.
    >> Share

  175. GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al
    Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049.
    >> Share

  176. TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046.
    >> Share

  177. AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al
    A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
    J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007.
    >> Share

  178. GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al
    Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials.
    J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004.
    >> Share

  179. BESSE B, Goto K, Wang Y, Lee SH, et al
    Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550.
    >> Share

  180. FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al
    A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548.
    >> Share

  181. DOWLATI A, Chiang AC, Cervantes A, Babu S, et al
    Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549.
    >> Share

  182. HUBER RM, Lam S, Cavic M, Balata H, et al
    Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript "Terminology Issues in Screening and Early Detection of Lung Cancer-International Association for the Study of Lung Cancer Early Detectio
    J Thorac Oncol. 2025;20:e6-e8.
    >> Share

  183. PENG J, Zhao L, Shan D
    Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e3-e4.
    >> Share

  184. GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al
    Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025;20:e11-e12.
    >> Share

  185. BORGHAEI H, Mok T
    Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
    J Thorac Oncol. 2025;20:17-19.
    >> Share

  186. LI HJ, Qiu ZB, Wang MM, Zhang C, et al
    Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:52-64.
    >> Share

  187. PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    J Thorac Oncol. 2025;20:76-93.
    >> Share

    December 2024
  188. WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al
    Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
    J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546.
    >> Share

  189. LEE JB, Choi SJ, Shim HS, Park BJ, et al
    Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
    J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544.
    >> Share

  190. GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al
    Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
    J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535.
    >> Share

  191. PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al
    Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529.
    >> Share

  192. SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al
    LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530.
    >> Share

  193. TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al
    Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531.
    >> Share

  194. HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surge
    J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526.
    >> Share

  195. KIM SY, Silvestri GA, Kim YW, Kim RY, et al
    Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.
    J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503.
    >> Share

  196. PHILLIPS WJ, Watson AS, Camidge DR
    The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
    J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498.
    >> Share

  197. XU X, Xie J, Luo Z
    Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer.
    J Thorac Oncol. 2024;19:e94-e95.
    >> Share

  198. LI Z, Liu J, Liu H, Wu C, et al
    Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology".
    J Thorac Oncol. 2024;19:e89-e90.
    >> Share

  199. ZHOU RX, Ye DW
    Reply to the Letter to the Editor: The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e82-e84.
    >> Share

  200. WANG L, Wang Z, Wang G
    The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e81-e82.
    >> Share

  201. JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e101-e102.
    >> Share

  202. NIU Y, Xie J, Li Z
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e100-e101.
    >> Share

  203. GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al
    Lung Cancer in Mozambique.
    J Thorac Oncol. 2024;19:1599-1605.
    >> Share

  204. TONG BC, Stinchcombe TE
    Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
    J Thorac Oncol. 2024;19:1589-1590.
    >> Share

  205. KOZONO D, Hua X, Wu MC, Tolba KA, et al
    Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    J Thorac Oncol. 2024;19:1618-1629.
    >> Share

    November 2024
  206. HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al
    Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer.
    J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488.
    >> Share

  207. KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al
    FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
    J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485.
    >> Share

  208. IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al
    Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484.
    >> Share

  209. DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al
    Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483.
    >> Share

  210. LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
    PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
    >> Share

  211. ZHAO S, Zhou H, Yang N, Wang Z, et al
    Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
    >> Share

  212. TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al
    Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.
    J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444.
    >> Share

  213. ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al
    DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
    J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438.
    >> Share

  214. GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al
    The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435.
    >> Share

  215. KARIM NA, Miao J, Reckamp KL, Gay CM, et al
    Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
    J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431.
    >> Share

  216. OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al
    Lung Cancer in Romania.
    J Thorac Oncol. 2024;19:1492-1503.
    >> Share

  217. D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al
    The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
    J Thorac Oncol. 2024;19:1479-1481.
    >> Share

  218. ADJEI AA
    How Can We Conquer Lung Cancer?
    J Thorac Oncol. 2024;19:1477-1478.
    >> Share

  219. KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1564-1577.
    >> Share

  220. PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al
    Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
    J Thorac Oncol. 2024;19:1539-1549.
    >> Share

  221. HONG TH, Hwang S, Dasgupta A, Abbosh C, et al
    Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
    J Thorac Oncol. 2024;19:1512-1524.
    >> Share

    October 2024
  222. HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al
    Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
    J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420.
    >> Share

  223. CHEN Z, Wu L, Wang Q, Yu Y, et al
    Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial.
    J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421.
    >> Share

  224. UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
    Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
    J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
    >> Share

  225. PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al
    Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
    J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355.
    >> Share

  226. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e57-e59.
    >> Share

  227. XU Z, Jiang J, Guo H, Zhao D, et al
    Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e56-e57.
    >> Share

  228. RAMI-PORTA R, Call S, Sanz-Santos J
    Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging" by Faria et al.
    J Thorac Oncol. 2024;19:e55-e56.
    >> Share

  229. FARIA N, Costa MI, Lacerda C, Sucena M, et al
    Impact of the Ninth International Association for the Study of Lung Cancer TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging.
    J Thorac Oncol. 2024;19:e53-e55.
    >> Share

  230. KOHNO T, Mochizuki A
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e52-e53.
    >> Share

  231. GU X, Han Z, Shi W
    Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".
    J Thorac Oncol. 2024;19:e51-e52.
    >> Share

  232. ZHUANG WT, Hu LY, Fang WF
    Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e50-e51.
    >> Share

  233. PAN Y
    Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e49-e50.
    >> Share

  234. SHI Y
    A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e48.
    >> Share

  235. GE MW, Chen HL
    Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e47-e48.
    >> Share

  236. CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O
    Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care.
    J Thorac Oncol. 2024;19:1367-1369.
    >> Share

  237. PUJOL JL, Erich Eberhardt WE
    Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening.
    J Thorac Oncol. 2024;19:1364-1366.
    >> Share

  238. SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al
    Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
    J Thorac Oncol. 2024;19:1449-1459.
    >> Share

  239. PAN K, Owens J, Elamin Y, Lu C, et al
    Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations.
    J Thorac Oncol. 2024;19:1438-1448.
    >> Share

  240. BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
    Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
    J Thorac Oncol. 2024;19:1460-1466.
    >> Share

    September 2024
  241. SAID BI, Geng Y, Badiyan SN, Bang A, et al
    Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
    J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
    >> Share

  242. PARK HS, Rimner A, Amini A, Chang JY, et al
    Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines.
    J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268.
    >> Share

  243. NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
    Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
    >> Share

  244. CHEN H, Yang S, Wang L, Wu Y, et al
    High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
    >> Share

  245. HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
    Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
    J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
    >> Share

  246. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e44-e45.
    >> Share

  247. JIANG Y, Zhang L
    Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e43.
    >> Share

  248. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
    J Thorac Oncol. 2024;19:e41-e43.
    >> Share

  249. ROMA L, Bubendorf L
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e38-e39.
    >> Share

  250. ZHOU L, Li M, Li W
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e37-e38.
    >> Share

  251. TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
    Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
    J Thorac Oncol. 2024;19:e36.
    >> Share

  252. NIU Y, Xie J, Li Z
    The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
    J Thorac Oncol. 2024;19:e34-e35.
    >> Share

  253. HIGASHIYAMA RI, Yoshida T
    A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    J Thorac Oncol. 2024;19:e33-e34.
    >> Share

  254. HAN Z, Liu L, Jiang Y
    Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
    J Thorac Oncol. 2024;19:e31-e32.
    >> Share

  255. ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
    Lung Cancer in Finland.
    J Thorac Oncol. 2024;19:1265-1271.
    >> Share

  256. YANG CY, Lee MR, Yang PC
    Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
    J Thorac Oncol. 2024;19:1261-1264.
    >> Share

  257. ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
    Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
    J Thorac Oncol. 2024;19:1352-1355.
    >> Share

  258. LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
    Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
    J Thorac Oncol. 2024;19:1297-1309.
    >> Share

  259. ROMA L, Ercan C, Conticelli F, Akyurek N, et al
    Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
    J Thorac Oncol. 2024;19:1284-1296.
    >> Share

  260. GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1310-1325.
    >> Share

    August 2024
  261. ZHOU Q, Meng X, Sun L, Huang D, et al
    Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study.
    J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762.
    >> Share

  262. HUBER RM, Cavic M, Balata H, Kitts AB, et al
    From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
    J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
    >> Share

  263. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e29-e30.
    >> Share

  264. KOSAKA N, Kataoka Y
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e28.
    >> Share

  265. CAMERON RB, Hines JB, Torri V, Garassino MC, et al
    A Response Letter by Cameron et al.
    J Thorac Oncol. 2024;19:e26-e28.
    >> Share

  266. HUANG J, Osarogiagbon RU
    Author's Reply.
    J Thorac Oncol. 2024;19:e24.
    >> Share

  267. PONVILAWAN B, Subramanian J, Bansal D
    The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
    J Thorac Oncol. 2024;19:e24-e26.
    >> Share

  268. TRISOLINI R
    The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024;19:e23.
    >> Share

  269. KUBO N
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e22.
    >> Share

  270. SHI L, Bao Z
    Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
    J Thorac Oncol. 2024;19:e21-e22.
    >> Share

  271. SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
    Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
    J Thorac Oncol. 2024;19:1155-1163.
    >> Share

  272. MAKAREM M, Janne PA
    "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1151-1154.
    >> Share

  273. ZHENG MM, Wu YL
    "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1146-1150.
    >> Share

  274. LAISAAR T, Innos K, Jaal J, Oselin K, et al
    Lung Cancer in Estonia.
    J Thorac Oncol. 2024;19:1138-1145.
    >> Share

  275. WOODARD GA, Jablons DM
    Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
    J Thorac Oncol. 2024;19:1135-1137.
    >> Share

  276. TURK MA
    Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024;19:1133-1134.
    >> Share

  277. PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
    Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
    J Thorac Oncol. 2024;19:1128-1132.
    >> Share

  278. GRAY SG, Mutti L, Meirson T
    Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
    J Thorac Oncol. 2024;19:1125-1127.
    >> Share

  279. HU LY, Zhuang WT, Chen MJ, Liao J, et al
    EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
    J Thorac Oncol. 2024;19:1186-1200.
    >> Share

  280. WOLF AS, Eisele M, Giroux DJ, Gill R, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1242-1252.
    >> Share

    July 2024
  281. VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al
    Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684.
    >> Share

  282. JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al
    Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
    J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683.
    >> Share

  283. GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
    Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
    J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
    >> Share

  284. JUN S, Shukla NA, Durm G, Hui AB, et al
    Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
    >> Share

  285. LIN YL, Wang GS, Wei JC
    Rheumatoid Arthritis and Risk of Lung Cancer.
    J Thorac Oncol. 2024;19:e15-e16.
    >> Share

  286. YANG JJ, Wen W, Zheng W, Shu XO, et al
    "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
    J Thorac Oncol. 2024;19:e14-e15.
    >> Share

  287. SHEN LT, Chen HL
    Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
    J Thorac Oncol. 2024;19:e13-e14.
    >> Share

  288. AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
    Lung Cancer in Ghana.
    J Thorac Oncol. 2024;19:966-972.
    >> Share

  289. MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
    Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
    J Thorac Oncol. 2024;19:984-994.
    >> Share

    June 2024
  290. SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
    Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
    >> Share

  291. HSU CK, Lai CC
    Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
    J Thorac Oncol. 2024;19:e9.
    >> Share

  292. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
    J Thorac Oncol. 2024;19:e11-e12.
    >> Share

  293. CHO MH, Cho JH, Shin DW
    In Response.
    J Thorac Oncol. 2024;19:e10.
    >> Share

  294. RICCIUTI B, Garassino MC
    Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
    J Thorac Oncol. 2024;19:877-882.
    >> Share

  295. DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
    The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
    J Thorac Oncol. 2024;19:862-865.
    >> Share

  296. UGALDE FIGUEROA P, Lacroix V, Van Schil PE
    Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
    J Thorac Oncol. 2024;19:858-861.
    >> Share

  297. LI MS, Ou SI
    Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
    J Thorac Oncol. 2024;19:855-857.
    >> Share

  298. PECCATORI FA, Florez N, Imbimbo M
    From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
    J Thorac Oncol. 2024;19:852-854.
    >> Share

    May 2024
  299. ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
    A real-world assessment of stage I lung cancer through electronic nose technology.
    J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
    >> Share

  300. BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
    >> Share

  301. NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
    >> Share

  302. NASSAR AH, Kim SY, Adib E, Naqash AR, et al
    Response letter by Nassar et al.
    J Thorac Oncol. 2024;19:e7-e8.
    >> Share

  303. CHEN CY, Wang GS, Wei JC
    Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    J Thorac Oncol. 2024;19:e6-e7.
    >> Share

  304. ZHAO B, Yao L, Ma W
    Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:e5-e6.
    >> Share

  305. SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
    Lung Cancer in Brunei Darussalam.
    J Thorac Oncol. 2024;19:698-705.
    >> Share

  306. LI Y, Adusumilli PS, Chou TY, Kadota K, et al
    Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:677-697.
    >> Share

  307. BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
    Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:671-676.
    >> Share

  308. SHIH JY
    ERBB2 Amplification in NSCLC: How Many Faces?
    J Thorac Oncol. 2024;19:668-670.
    >> Share

  309. ISHIKAWA S
    Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
    J Thorac Oncol. 2024;19:666-667.
    >> Share

  310. WOODARD GA, Dacic S
    Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
    J Thorac Oncol. 2024;19:663-665.
    >> Share

  311. LUO J, Sanchez M, Lee E, Hertzler H, et al
    Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
    J Thorac Oncol. 2024;19:829-838.
    >> Share

  312. OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
    Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
    J Thorac Oncol. 2024;19:706-718.
    >> Share

    April 2024
  313. GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
    Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
    J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
    >> Share

  314. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
    Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
    >> Share

  315. HORNE A, Harada K, Brown KD, Chua KLM, et al
    Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
    >> Share

  316. KIM IH, Lee GD, Choi S, Kim HR, et al
    Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
    >> Share

  317. SHUKLA V, Wang H, Varticovski L, Baek S, et al
    Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
    >> Share

  318. DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
    >> Share

  319. CHANG CL, Lin KC, Chen WM, Shia BC, et al
    Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e2-e4.
    >> Share

  320. CHIOU CC, Lai TY
    Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e1-e2.
    >> Share

  321. SMESSEIM I, Baas P
    Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
    J Thorac Oncol. 2024;19:547-550.
    >> Share

  322. GRAY SG, Meirson T, Mutti L
    Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
    J Thorac Oncol. 2024;19:541-546.
    >> Share

  323. SAIFO M, Alali M, Alhabeb H, Awak M, et al
    Lung Cancer in Syria.
    J Thorac Oncol. 2024;19:534-540.
    >> Share

  324. SHOENBILL KA, Goldstein AO
    Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
    J Thorac Oncol. 2024;19:531-533.
    >> Share

  325. ZHU Z, Chen H
    Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
    J Thorac Oncol. 2024;19:528-530.
    >> Share

  326. LEE JB, Nagasaka M
    Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
    J Thorac Oncol. 2024;19:525-527.
    >> Share

  327. LEONG TL, McWilliams A, Wright GM
    Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
    J Thorac Oncol. 2024;19:522-524.
    >> Share

  328. DWYER LJ, Singhal N, Yu B, Kao S, et al
    Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
    J Thorac Oncol. 2024;19:650-652.
    >> Share

  329. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
    Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
    J Thorac Oncol. 2024;19:626-635.
    >> Share

  330. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
    Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    J Thorac Oncol. 2024;19:636-642.
    >> Share

  331. NEL AE, Pavlisko EN, Roggli VL
    The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
    J Thorac Oncol. 2024;19:551-564.
    >> Share

    March 2024
  332. TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
    The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
    J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
    >> Share

  333. BORGEAUD M, Parikh K, Banna GL, Kim F, et al
    Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
    J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
    >> Share

  334. HINES JB, Cameron RB, Esposito A, Kim L, et al
    Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
    J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
    >> Share

  335. CHENG Y, Fan Y, Zhao Y, Huang D, et al
    Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
    J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
    >> Share

  336. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
    >> Share

  337. KIM BG, Yoon S, Lee SY, Sohn JW, et al
    How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
    J Thorac Oncol. 2024;19:509-510.
    >> Share

  338. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
    Lung Cancer in Switzerland.
    J Thorac Oncol. 2024;19:385-394.
    >> Share

  339. TEN HAAF K
    Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
    J Thorac Oncol. 2024;19:373-375.
    >> Share

  340. LI CP, Tsai RY, Chang HC, Gau SY, et al
    Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:507-508.
    >> Share

  341. CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
    Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:380-384.
    >> Share

  342. LIM SM, Lee JB, Cho BC
    Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:376-379.
    >> Share

  343. YALAMANCHALI A, Hassan KA
    MUC1-C: The Occam Razor of Osimertinib Resistance?
    J Thorac Oncol. 2024;19:370-372.
    >> Share

  344. DAMMEIJER F, Dumoulin DW, Aerts JGJV
    Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
    J Thorac Oncol. 2024;19:366-369.
    >> Share

  345. CANI M, Novello S, Bironzo P
    Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
    J Thorac Oncol. 2024;19:363-365.
    >> Share

  346. BORCZUK AC
    Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
    J Thorac Oncol. 2024;19:360-362.
    >> Share

  347. YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
    Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
    J Thorac Oncol. 2024;19:409-424.
    >> Share

    February 2024
  348. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
    >> Share

  349. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
    Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
    >> Share

  350. TORASAWA M, Horinouchi H
    A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
    J Thorac Oncol. 2024;19:351-352.
    >> Share

  351. NISHIMURA T
    A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
    J Thorac Oncol. 2024;19:350.
    >> Share

  352. HORITA N, Takase-Minegishi K
    Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
    J Thorac Oncol. 2024;19:348.
    >> Share

  353. CHANG HC, Gau SY
    Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:346.
    >> Share

  354. YUAN C, Huang R, Wang Y
    An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
    J Thorac Oncol. 2024;19:344-345.
    >> Share

  355. BERMAS BL, Gerber DE
    The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:196-198.
    >> Share

  356. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
    Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
    J Thorac Oncol. 2024;19:285-296.
    >> Share

  357. REMON J, Saw SPL, Cortiula F, Singh PK, et al
    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
    J Thorac Oncol. 2024;19:199-215.
    >> Share

  358. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
    Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
    J Thorac Oncol. 2024;19:273-284.
    >> Share

  359. OWONIKOKO TK
    SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
    J Thorac Oncol. 2024;19:193-195.
    >> Share

  360. LE X
    Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:190-192.
    >> Share

  361. LEE JH
    Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
    J Thorac Oncol. 2024;19:187-189.
    >> Share

  362. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
    Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
    J Thorac Oncol. 2024;19:337-343.
    >> Share

    January 2024
  363. SHI Y, Hu X, Li X, Gong C, et al
    Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
    J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
    >> Share

  364. SHI Y, Chen J, Yang R, Wu H, et al
    Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
    J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
    >> Share

  365. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
    Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
    >> Share

  366. SIMONS E, Camidge DR
    Lung cancer oncogene-directed therapy, fertility and pregnancy.
    J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
    >> Share

  367. YU S, Feng J
    Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
    J Thorac Oncol. 2024;19:173-174.
    >> Share

  368. TANIZAKI J, Hayashi H
    Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
    J Thorac Oncol. 2024;19:15-17.
    >> Share

  369. BATAH H, Majeed Z, Moudgil R
    Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
    J Thorac Oncol. 2024;19:13-14.
    >> Share

  370. SINGHAL S, Gandara D, Riess JW
    Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
    J Thorac Oncol. 2024;19:10-12.
    >> Share

  371. FANG W, Girard N, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2024;19:52-70.
    >> Share

  372. CHEN MF, Harada G, Liu D, DeMatteo R, et al
    Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
    J Thorac Oncol. 2024;19:153-159.
    >> Share

  373. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
    HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    J Thorac Oncol. 2024;19:106-118.
    >> Share

  374. HAMADA A, Suda K, Nishino M, Obata K, et al
    Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    J Thorac Oncol. 2024;19:71-79.
    >> Share

  375. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
    The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
    J Thorac Oncol. 2024;19:94-105.
    >> Share

  376. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
    Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:166-172.
    >> Share

    December 2023
  377. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
    Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
    J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
    >> Share

  378. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
    Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
    >> Share

  379. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
    Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
    J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
    >> Share

  380. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
    >> Share

  381. LI W, Fei K, Guo L, Wang Y, et al
    CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
    >> Share

  382. DACIC S, Travis WD, Giltnane JM, Kos F, et al
    Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
    >> Share

  383. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.
    >> Share

  384. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.
    >> Share

  385. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.
    >> Share

  386. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.
    >> Share

  387. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    >> Share

  388. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    >> Share

  389. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    >> Share

  390. ANG YLE, Soo RA
    Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
    J Thorac Oncol. 2023;18:1621-1624.
    >> Share

  391. MEDINA CG, Xu Y, Ripley RT
    International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
    J Thorac Oncol. 2023;18:1618-1620.
    >> Share

  392. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
    J Thorac Oncol. 2023;18:1756-1766.
    >> Share

  393. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:1689-1702.
    >> Share

    November 2023
  394. WANG K, Du R, Myall NJ, Lewis WE, et al
    BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
    >> Share

  395. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
    Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
    >> Share

  396. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    >> Share

  397. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    >> Share

  398. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    >> Share

  399. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    >> Share

  400. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    >> Share

  401. YANG JJ, Wen W, Zahed H, Zheng W, et al
    Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
    J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
    >> Share

  402. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
    Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
    >> Share

  403. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
    MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
    >> Share

  404. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    >> Share

  405. QIU Z, Huang H, Zhang Y, Chen D, et al
    Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
    J Thorac Oncol. 2023;18:e138-e139.
    >> Share

  406. LI A, Yang Y, Zhang L, Hong S, et al
    STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
    J Thorac Oncol. 2023;18:e135-e138.
    >> Share

  407. AMORI G, Sugawara E, Inamura K
    Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
    J Thorac Oncol. 2023;18:e134-e135.
    >> Share

  408. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e132-e134.
    >> Share

  409. ZHANG Y, Dai K, He D, Chen Z, et al
    The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e130-e131.
    >> Share

  410. NIU Y, Yao F, Yang H
    "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
    J Thorac Oncol. 2023;18:e126-e128.
    >> Share

  411. MARTI JLG, Wells JZ, Wells A
    Statins as a Secondary Preventive Agent for Metastatic Cancer.
    J Thorac Oncol. 2023;18:e125-e126.
    >> Share

  412. OKONTA KE, Baiyewu LA, Jimoh MA
    Lung Cancer in Nigeria.
    J Thorac Oncol. 2023;18:1446-1457.
    >> Share

  413. DAGOGO-JACK I
    We Don't Talk (Enough) About BRAF.
    J Thorac Oncol. 2023;18:1443-1445.
    >> Share

  414. LEE JB, Ou SI
    Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
    J Thorac Oncol. 2023;18:1434-1442.
    >> Share

  415. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
    A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    J Thorac Oncol. 2023;18:1431-1433.
    >> Share

  416. SOZZI G, Pastorino U
    Small RNAs Do It Better.
    J Thorac Oncol. 2023;18:1428-1430.
    >> Share

  417. YANKELEVITZ DF, Yip R, Henschke CI
    Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
    J Thorac Oncol. 2023;18:1426-1427.
    >> Share

  418. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
    Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
    J Thorac Oncol. 2023;18:1538-1549.
    >> Share

  419. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
    Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    J Thorac Oncol. 2023;18:1594-1606.
    >> Share

    October 2023
  420. WANG L, Luo Y, Ren S, Zhang Z, et al
    A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
    J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
    >> Share

  421. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
    >> Share

  422. CHO MH, Cho JH, Eun Y, Han K, et al
    Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
    J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
    >> Share

  423. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
    >> Share

  424. HENSCHKE CI, Yip R, Sun Q, Li P, et al
    Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
    >> Share

  425. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
    Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
    >> Share

  426. TRIPHURIDET N, Gao Y, Ou SI
    Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
    J Thorac Oncol. 2023;18:e122-e123.
    >> Share

  427. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
    Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
    J Thorac Oncol. 2023;18:e118-e122.
    >> Share

  428. CHOUR A, Duruisseaux M
    Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
    J Thorac Oncol. 2023;18:e114-e115.
    >> Share

  429. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
    The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
    J Thorac Oncol. 2023;18:1258-1260.
    >> Share

  430. INAMURA K
    Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
    J Thorac Oncol. 2023;18:e109-e110.
    >> Share

  431. ADJEI AA
    The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
    J Thorac Oncol. 2023;18:1257.
    >> Share

  432. HOE HJ, Balasubramanian A, John T
    LASERing FLAURAL Arrangements in Asian EGFR Subsets.
    J Thorac Oncol. 2023;18:1261-1264.
    >> Share

  433. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
    Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    J Thorac Oncol. 2023;18:1351-1361.
    >> Share

  434. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
    Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
    J Thorac Oncol. 2023;18:1362-1385.
    >> Share

  435. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
    Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
    J Thorac Oncol. 2023;18:e112-e113.
    >> Share

  436. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
    J Thorac Oncol. 2023;18:e107-e109.
    >> Share

  437. LIN TA, Chen SY, Chang R, Sun CK, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:e105-e106.
    >> Share

  438. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
    Malignant Superior Vena Cava Syndrome: A Scoping Review.
    J Thorac Oncol. 2023;18:1268-1276.
    >> Share

  439. EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
    Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot.
    J Thorac Oncol. 2023;18:1323-1333.
    >> Share

    September 2023
  440. DUAN J, Wu L, Yang K, Zhao J, et al
    Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
    J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
    >> Share

  441. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
    Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
    >> Share

  442. JIANG C, Zhang Y, Fu F, Deng P, et al
    A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
    >> Share

  443. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
    Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
    >> Share

  444. WANG X, Bai H, Zhang J, Wang Z, et al
    Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
    >> Share

  445. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
    Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
    >> Share

  446. ZHANG S, Liu L, Shi S, He H, et al
    Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
    J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
    >> Share

    August 2023
  447. DACIC S, Travis W, Redman M, Saqi A, et al
    International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
    >> Share

  448. LIN SH
    Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
    J Thorac Oncol. 2023;18:970-971.
    >> Share

    July 2023
  449. RIMNER A, Ruffini E, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
    >> Share

    June 2023
  450. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
    Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016